ClinicalTrials.gg
RecruitingNCT03785080NOAC-GAPUpdated May 5, 2020

Non-warfarin Oral AntiCoagulant Resumption After Gastrointestinal Bleeding in Atrial Fibrillation Patients

An interventional study of restart NOAC very early and restart NOAC early in Upper Gastrointestinal Bleeding, sponsored by Chinese University of Hong Kong. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-05-05.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2019; still recruiting 7 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
552
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Gastrointestinal Hemorrhage by Chinese University of Hong Kong — 4 open to participants now, 4 under way, none of them phase 3. Gastrointestinal Hemorrhage · Chinese University of Hong Kong.

Planned enrollment
3rd of 15
552 · median 216
Started
2019
with 1 other
No phase
10 of 17
3 open now
Registered
11th of 17
by date

Among the 17 studies in Gastrointestinal Hemorrhage by Chinese University of Hong Kong, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2019, is one of 10 with no phase, and was the 11th registered.

Gastrointestinal Hemorrhage

338 studies on the registry are indexed under Gastrointestinal Hemorrhage; 77 are open to participants now.

Browse Gastrointestinal Hemorrhage studies →

Open to participants now

4 of the 17 studies in Gastrointestinal Hemorrhage by Chinese University of Hong Kong are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 49 Gastrointestinal Hemorrhage studies recruiting now, 39 (80%) set no upper age limit and 4 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Gastrointestinal Hemorrhage by Chinese University of Hong Kong, or all of them as a file.
02

Study summary

Current clinical society guidelines and statements are non-specific and relatively open-ended regarding the optimal timing to restart non-warfarin oral anticoagulant (NOAC) after gastrointestinal bleeding (GIB) in patients with atrial fibrillation (AF) who require the prophylactic medication for stroke prevention. These patients are at increased risk for devastating future thromboembolic events including stroke if NOAC is not resumed promptly, whilst premature resumption of anticoagulants can result in recurrent GIB, haemorrhage, anaemia, myocardial ischaemia and infarction in those with ischaemic heart disease, and even death. However, the question as to how early a NOAC can be safely restarted after acute GIB has not been previously answered, and there remains an important knowledge gap.

Read the detailed description

The effectiveness and relative safety of NOACs have been demonstrated in large international studies where reductions in the incidence of stroke in patients with AF have been reported. However, the benefits of an anticoagulant are offset by increased incident rates of bleeding including gastrointestinal bleeding (GIB) and, less commonly, intracranial bleeding, warranting careful anticoagulation management during periods when patients are susceptible to the risks for bleeding, stroke and thromboembolism.

The exact duration for withholding NOAC after acute GIB is unknown and in general, current clinical society guidelines and statements are non-specific and relatively open-ended regarding the optimal timing to restart non-warfarin oral anticoagulant (NOAC) after gastrointestinal bleeding (GIB) in patients with atrial fibrillation (AF) who require the prophylactic medication for stroke prevention. These patients are at increased risk for devastating future thromboembolic events including stroke if NOAC is not resumed, whilst premature resumption of anticoagulants can result in recurrent GIB, haemorrhage, anaemia, myocardial ischaemia and infarction in those with ischaemic heart disease, and even death.

The purpose of this study is to determine if restarting NOAC very early after endoscopic haemostasis of bleeding peptic ulcer lesions is equivalent to early resumption in AF patients in terms of safety and efficacy for prevention of recurrent bleeding freedom from GIB recurrence, while maintaining undiminished benefits in reducing incident rates of systemic thromboembolism.

03

Conditions studied

  • Upper Gastrointestinal Bleeding

Keywords

  • gastrointestinal bleeding
  • stroke
  • thromboembolism
  • atrial fibrillation
  • NOAC
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • History of AF
  • Taking any kind of NOAC at the time of index acute GIB
  • Acute upper GIB (non-variceal bleeding lesions accounting for the GIB) with or without endoscopic treatment confirmed endoscopic haemostasis verified by GI specialist
  • Patient or next-of-kin able to provide

Exclusion criteria

Exclusion Criteria:

  • Concomitant stroke (including ) at the time of index GIB
  • Requiring bridging IV heparin therapy
  • Portal hypertension
  • Known bleeding diathesis
  • Other conditions precluding use of NOAC at the time of randomisation

    • Pregnancy
    • Tumour bleeding
    • Antidote administration to reverse anticoagulation effect of NOACs
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
552 participants (estimated)

Study arms

  • Experimental
    restart NOAC very early

    restart NOAC within 24 hours

    Other: restart NOAC very early

  • Active comparator
    restart NOAC early

    restart NOAC at 72 - 84 hours

    Other: restart NOAC early

Interventions

  • Otherrestart NOAC very early

    withhold NOAC less than 24 hours Post OGD

  • Otherrestart NOAC early

    withhold NOAC for 72 to 84 hours Post OGD

06

What researchers measure

Primary outcomes

  1. recurrent gastrointestinal bleeding

    melaena and/or haematemesis with drop in Hb \>2g/dL and confirmation of bleeding by endoscopy.

    Time frame: 30 days

Secondary outcomes

  1. recurrent gastrointestinal bleeding

    melaena and/or haematemesis with drop in Hb \>2g/dL and confirmation of bleeding by endoscopy.

    Time frame: 90 days

  2. Ischemic stroke or transient ischaemic attack

    an acute episode of neurologic deficit of presumed vascular or cardioembolic origin; its presence will be confirmed by a member of the neurology service

    Time frame: 30 days

  3. Systemic thromboembolism

    any clinical and/or radiographic acute stroke and/or an acute peripheral arterial thromboembolic event including acute limb ischaemia, coronary embolism and arterial thromboembolism

    Time frame: 30 days

  4. Death

    All-cause mortality

    Time frame: 6 months

07

Study locations

3 of 3 sites recruiting
  • Blacktown Hospital
    Blacktown, New South Wales, Australia
    Recruiting
    • Raymond KWOK, MD · Contact
  • Endoscopy Center, Prince of Wales Hospital
    Hong Kong, Hong Kong
    Recruiting
    • Joseph SUNG, MD · Contactjjysung@cuhk.edu.hk · +852 3505 3132
    • Bing Yee SUEN, BSN · Contactsuenbingyee@cuhk.edu.hk · +852 3505 2640
    • Joseph SUNG, MD · Principal investigator
    • Erik FUNG, MD · Principal investigator
  • National University Hospital
    Singapore, Singapore
    Recruiting
    • Jimmy SO · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for Jun 2024, 63 months after the start.

Of 63 non-industry interventional studies with no phase under Gastrointestinal Hemorrhage, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 42. This study's planned 63 months is above that.

Counting every sponsor, half of 73 studies reached it within 22 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2018
First posted
Dec 24, 2018
StartActual
Mar 11, 2019
Primary completionEst.
Jun 30, 2024
CompletionEst.
Dec 30, 2025
Last update
May 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03785080
Responsible party
Joseph JY SUNG (Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Dec 24, 2018
Start date
Mar 11, 2019
Primary completion
Jun 30, 2024 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
May 5, 2020

Study contacts

Bing Yee SUEN, BSN
Contact
suenbingyee@cuhk.edu.hk
+852 3505 2640
Ming Yeung HO, BSc
Contact
andrewho@cuhk.edu.hk
+852 2637 1398
Joseph SUNG, MD
principal investigator · CUHK

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion